Rapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at HC Wainwright

Key Points

• HC Wainwright has initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) with a "buy" rating and a price target of $31.00, indicating a potential upside of 114.83% from its current price.
• Insider David Bredt sold 8,500 shares of Rapport Therapeutics at an average price of $14.00, reducing his ownership in the company by 1.92%.
• Several institutional investors significantly increased their holdings in Rapport Therapeutics, including Legal & General Group Plc, which grew its stake by 947.6% during the fourth quarter.

Analysts at HC Wainwright began coverage on shares of Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm set a "buy" rating and a $31.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 113.06% from the company's current price. HC Wainwright also issued estimates for Rapport Therapeutics' Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($3.14) EPS, FY2027 earnings at ($3.64) EPS, FY2028 earnings at ($4.44) EPS and FY2029 earnings at ($4.07) EPS.

Other equities analysts also recently issued research reports about the company. Citizens Jmp assumed coverage on Rapport Therapeutics in a research report on Tuesday, April 8th. They set a "mkt outperform" rating on the stock. JMP Securities reiterated a "market outperform" rating and set a $28.00 price objective on shares of Rapport Therapeutics in a research report on Tuesday, July 8th.

Rapport Therapeutics Price Performance

Shares of NASDAQ RAPP traded down $0.86 during midday trading on Wednesday, reaching $14.55. 104,519 shares of the stock traded hands, compared to its average volume of 165,562. The company's 50 day moving average is $13.21 and its 200 day moving average is $11.95. Rapport Therapeutics has a one year low of $6.43 and a one year high of $29.74. The stock has a market capitalization of $531.08 million, a PE ratio of -5.82 and a beta of 0.62.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.12. As a group, equities analysts forecast that Rapport Therapeutics will post -3.65 EPS for the current year.

Insider Buying and Selling at Rapport Therapeutics

In related news, insider David Bredt sold 8,500 shares of the business's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $14.00, for a total transaction of $119,000.00. Following the completion of the transaction, the insider owned 435,142 shares in the company, valued at $6,091,988. The trade was a 1.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Trading of Rapport Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RAPP. Legal & General Group Plc raised its position in Rapport Therapeutics by 947.6% during the 4th quarter. Legal & General Group Plc now owns 9,523 shares of the company's stock valued at $169,000 after purchasing an additional 8,614 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Rapport Therapeutics in the fourth quarter valued at approximately $34,000. GAMMA Investing LLC increased its stake in shares of Rapport Therapeutics by 91,980.0% during the first quarter. GAMMA Investing LLC now owns 9,208 shares of the company's stock worth $918,000 after purchasing an additional 9,198 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Rapport Therapeutics by 1,151.2% in the 4th quarter. California State Teachers Retirement System now owns 8,571 shares of the company's stock valued at $152,000 after purchasing an additional 7,886 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Rapport Therapeutics by 43.8% during the 4th quarter. Barclays PLC now owns 18,497 shares of the company's stock worth $328,000 after purchasing an additional 5,634 shares during the last quarter.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.